ANNEX I

SUMMARY OF PRODUCT CHARACTERISTICS
1. **NAME OF THE MEDICINAL PRODUCT**

FOSAVANCE tablets

2. **QUALITATIVE AND QUANTITATIVE COMPOSITION**

Each tablet contains 70 mg alendronic acid as alendronate sodium trihydrate and 70 micrograms (2800 IU) colecalciferol (vitamin D₃).

For excipients, see section 6.1.

3. **PHARMACEUTICAL FORM**

Tablet.

Capsule-shaped, white to off-white tablets, marked with an outline of a bone image on one side, and '710' on the other.

4. **CLINICAL PARTICULARS**

4.1 **Therapeutic indications**

Treatment of postmenopausal osteoporosis in patients at risk of vitamin D insufficiency. FOSAVANCE reduces the risk of vertebral and hip fractures.

4.2 **Posology and method of administration**

The recommended dosage is one (70 mg/70 microgram) tablet once weekly.

Due to the nature of the disease process in osteoporosis, FOSAVANCE is intended for long-term use.

*To permit adequate absorption of alendronate:*

FOSAVANCE must be taken with water only (not mineral water) at least 30 minutes before the first food, beverage, or medicinal product (including antacids, calcium supplements and vitamins) of the day. Other beverages (including mineral water), food and some medicinal products are likely to reduce the absorption of alendronate (see section 4.5).

*The following instructions should be followed exactly in order to minimize the risk of oesophageal irritation and related adverse reactions (see section 4.4):*

- FOSAVANCE should only be swallowed upon arising for the day with a full glass of water (not less than 200ml or 7fl.oz.).
- Patients should not chew the tablet or allow the tablet to dissolve in their mouths because of a potential for oropharyngeal ulceration.
- Patients should not lie down until after their first food of the day which should be at least 30 minutes after taking the tablet.
- Patients should not lie down for at least 30 minutes after taking FOSAVANCE.
- FOSAVANCE should not be taken at bedtime or before arising for the day.
Patients should receive supplemental calcium if intake is inadequate (see section 4.4). Additional supplementation with vitamin D should be considered on an individual basis taking into account any vitamin D intake from vitamins and dietary supplements. Equivalence of 2800 IU of vitamin D₃ weekly in FOSAVANCE to daily dosing of vitamin D 400 IU has not been studied.

Use in the elderly:
In clinical studies there was no age-related difference in the efficacy or safety profiles of alendronate. Therefore no dosage adjustment is necessary for the elderly.

Use in renal impairment:
No dosage adjustment is necessary for patients with glomerular filtration rate (GFR) greater than 35ml/min. FOSAVANCE is not recommended for patients with renal impairment where GFR is less than 35ml/min, due to lack of experience.

Use in children and adolescents:
FOSAVANCE has not been studied in children and adolescents and therefore should not be given to them.

4.3 Contraindications

- Hypersensitivity to the active substances or to any of the excipients.
- Abnormalities of the oesophagus and other factors which delay oesophageal emptying such as stricture or achalasia.
- Inability to stand or sit upright for at least 30 minutes.
- Hypocalcaemia.

4.4 Special warnings and precautions for use

Alendronate
Alendronate can cause local irritation of the upper gastrointestinal mucosa. Because there is a potential for worsening of the underlying disease, caution should be used when alendronate is given to patients with active upper gastrointestinal problems, such as dysphagia, oesophageal disease, gastritis, duodenitis, ulcers, or with a recent history (within the previous year) of major gastrointestinal disease such as peptic ulcer, or active gastrointestinal bleeding, or surgery of the upper gastrointestinal tract other than pyloroplasty (see section 4.3).

Oesophageal reactions (sometimes severe and requiring hospitalisation), such as oesophagitis, oesophageal ulcers and oesophageal erosions, rarely followed by oesophageal stricture, have been reported in patients receiving alendronate. Physicians should therefore be alert to any signs or symptoms signalling a possible oesophageal reaction and patients should be instructed to discontinue alendronate and seek medical attention if they develop symptoms of oesophageal irritation such as dysphagia, pain on swallowing or retrosternal pain, new or worsening heartburn (see section 4.8).

The risk of severe oesophageal adverse reactions appears to be greater in patients who fail to take alendronate properly and/or who continue to take alendronate after developing symptoms suggestive of oesophageal irritation. It is very important that the full dosing instructions are provided to, and understood by the patient (see section 4.2). Patients should be informed that failure to follow these instructions may increase their risk of oesophageal problems.

While no increased risk was observed in extensive clinical trials with alendronate, there have been rare (post-marketing) reports of gastric and duodenal ulcers, some severe and with complications. A causal relationship cannot be ruled out (see section 4.8).
Bone, joint, and/or muscle pain has been reported in patients taking bisphosphonates. In post-marketing experience, these symptoms have rarely been severe and/or incapacitating (see section 4.8). The time to onset of symptoms varied from one day to several months after starting treatment. Most patients had relief of symptoms after stopping treatment. A subset had recurrence of symptoms when rechallenged with the same medicinal product or another bisphosphonate.

Patients should be instructed that if they miss a dose of FOSAVANCE they should take one tablet on the morning after they remember. They should not take two tablets on the same day but should return to taking one tablet once a week, as originally scheduled on their chosen day.

FOSAVANCE is not recommended for patients with renal impairment where GFR is less than 35ml/min (see section 4.2).

Causes of osteoporosis other than oestrogen deficiency and ageing should be considered.

Hypocalcaemia must be corrected before initiating therapy with FOSAVANCE (see section 4.3). Other disorders affecting mineral metabolism (such as vitamin D deficiency and hypoparathyroidism) should also be effectively treated before starting FOSAVANCE. The content of vitamin D in FOSAVANCE is not suitable for correction of vitamin D deficiency. In patients with these conditions, serum calcium and symptoms of hypocalcaemia should be monitored during therapy with FOSAVANCE.

Due to the positive effects of alendronate in increasing bone mineral, decreases in serum calcium and phosphate may occur. These are usually small and asymptomatic. However, there have been rare reports of symptomatic hypocalcaemia, which have occasionally been severe and often occurred in patients with predisposing conditions (e.g. hypoparathyroidism, vitamin D deficiency and calcium malabsorption) (see section 4.8).

Colecaltiferol
Vitamin D₃ may increase the magnitude of hypercalcaemia and/or hypercalciuria when administered to patients with disease associated with unregulated overproduction of calcitriol (e.g. leukaemia, lymphoma, sarcoidosis). Urine and serum calcium should be monitored in these patients.

Patients with malabsorption may not adequately absorb vitamin D₃.

Excipients
This medicinal product contains lactose and sucrose. Patients with rare hereditary problems of fructose intolerance, galactose intolerance, the Lapp lactase deficiency, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicinal product.

4.5 Interaction with other medicinal products and other forms of interaction

Alendronate
If taken at the same time, it is likely that food and beverages (including mineral water), calcium supplements, antacids, and some oral medicinal products will interfere with absorption of alendronate. Therefore, patients must wait at least 30 minutes after taking alendronate before taking any other oral medicinal product (see sections 4.2 and 5.2).

No other interactions with medicinal products of clinical significance are anticipated. A number of patients in the clinical trials received oestrogen (intravaginal, transdermal, or oral) while taking alendronate. No adverse reactions attributable to their concomitant use were identified.

Although specific interaction studies were not performed, in clinical studies alendronate was used concomitantly with a wide range of commonly prescribed medicinal products without evidence of interactions of clinical relevance.
Colecalciferol
Olestra, mineral oils, orlistat, and bile acid sequestrants (e.g. cholestyramine, colestipol) may impair the absorption of vitamin D. Anticonvulsants, cimetidine and thiazides may increase the catabolism of vitamin D. Additional vitamin D supplements may be considered on an individual basis.

4.6 Pregnancy and lactation

FOSAVANCE is only intended for use in postmenopausal women and therefore it should not be used during pregnancy or in breast-feeding women. There are no adequate data from the use of FOSAVANCE in pregnant women. Animal studies with alendronate do not indicate direct harmful effects with respect to pregnancy, embryonal/foetal development, or postnatal development. Alendronate given during pregnancy in rats caused dystocia related to hypocalcaemia (see section 5.3). Studies in animals have shown hypercalcaemia and reproductive toxicity with high doses of vitamin D (see section 5.3).

It is not known whether alendronate is excreted into human breast milk. Colecalciferol and some of its active metabolites pass into breast milk.

4.7 Effects on ability to drive and use machines

No studies on the effects on the ability to drive and use machines have been performed. However, there is no information to indicate that FOSAVANCE affects a patient’s ability to drive or operate machines.

4.8 Undesirable effects

The following adverse reactions have been reported during clinical studies and/or post-marketing use with alendronate.

No new adverse reactions have been identified for FOSAVANCE.

[Common (≥1/100, < 1/10), Uncommon (≥1/1000, < 1/100), Rare (≥1/10,000, < 1/1000), Very rare (< 1/10,000 including isolated cases)]

**Immune system disorders:**
Rare: hypersensitivity reactions including urticaria and angioedema

**Metabolism and nutrition disorders:**
Rare: symptomatic hypocalcaemia, often in association with predisposing conditions. (see section 4.4)

**Nervous system disorders:**
Common: headache

**Eye disorders:**
Rare: uveitis, scleritis, episcleritis

**Gastrointestinal disorders:**
Common: abdominal pain, dyspepsia, constipation, diarrhoea, flatulence, oesophageal ulcer*, dysphagia*, abdominal distension, acid regurgitation

Uncommon: nausea, vomiting, gastritis, oesophagitis*, oesophageal erosions*, melena
Rare: oesophageal stricture*, oropharyngeal ulceration*, upper gastrointestinal PUBs (perforation, ulcers, bleeding)(see section 4.4); localised osteonecrosis of the jaw, generally associated with tooth extraction and/or local infection, often with delayed healing.

*See sections 4.2 and 4.4

Skin and subcutaneous tissue disorders:
Uncommon: rash, pruritus, erythema
Rare: rash with photosensitivity

Very rare and isolated cases: isolated cases of severe skin reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis

Musculoskeletal, connective tissue and bone disorders:
Common: musculoskeletal (bone, muscle or joint) pain
Rare: severe musculoskeletal (bone, muscle or joint) pain (see section 4.4)

General disorders and administration site conditions:
Rare: transient symptoms as in an acute-phase response (myalgia, malaise and rarely, fever), typically in association with initiation of treatment.

Laboratory test findings
In clinical studies, asymptomatic, mild and transient decreases in serum calcium and phosphate were observed in approximately 18 % and 10 %, respectively, of patients taking alendronate 10 mg/day versus approximately 12 % and 3 % of those taking placebo. However, the incidences of decreases in serum calcium to < 8.0 mg/dl (2.0 mmol/l) and serum phosphate to ≤ 2.0 mg/dl (0.65 mmol/l) were similar in both treatment groups.

4.9 Overdose

Alendronate
Hypocalcaemia, hypophosphataemia and upper gastrointestinal adverse reactions, such as upset stomach, heartburn, oesophagitis, gastritis, or ulcer, may result from oral overdosage.

No specific information is available on the treatment of overdosage with alendronate. In case of overdosage with FOSAVANCE, milk or antacids should be given to bind alendronate. Owing to the risk of oesophageal irritation, vomiting should not be induced and the patient should remain fully upright.

Colecalciferol
Vitamin D toxicity has not been documented during chronic therapy in generally healthy adults at a dose less than 10,000 IU/day. In a clinical study of healthy adults a 4000 IU daily dose of vitamin D₃ for up to five months was not associated with hypercalciuria or hypercalcaemia.
5. PHARMACOLOGICAL PROPERTIES

5.1. Pharmacodynamic properties

Pharmacotherapeutic group: Drugs for treatment of bone diseases [pending]
ATC code: M05XX [pending]

FOSAVANCE is a combination tablet containing the two active substances alendronate sodium trihydrate and colecalciferol (vitamin D₃).

Alendronate

Alendronate sodium is a bisphosphonate that inhibits osteoclastic bone resorption with no direct effect on bone formation. Preclinical studies have shown preferential localisation of alendronate to sites of active resorption. Activity of osteoclasts is inhibited, but recruitment or attachment of osteoclasts is not affected. The bone formed during treatment with alendronate is of normal quality.

Colecalciferol (vitamin D₃)

Vitamin D₃ is produced in the skin by conversion of 7-dehydrocholesterol to vitamin D₃ by ultraviolet light. In the absence of adequate sunlight exposure, vitamin D₃ is an essential dietary nutrient. Vitamin D₃ is converted to 25-hydroxyvitamin D₃ in the liver, and stored until needed. Conversion to the active calcium-mobilizing hormone 1,25-dihydroxyvitamin D₃ (calcitriol) in the kidney is tightly regulated. The principal action of 1,25-dihydroxyvitamin D₃ is to increase intestinal absorption of both calcium and phosphate as well as regulate serum calcium, renal calcium and phosphate excretion, bone formation and bone resorption.

Vitamin D₃ is required for normal bone formation. Vitamin D insufficiency develops when both sunlight exposure and dietary intake are inadequate. Insufficiency is associated with negative calcium balance, bone loss, and increased risk of skeletal fracture. In severe cases, deficiency results in secondary hyperparathyroidism, hypophosphataemia, proximal muscle weakness and osteomalacia, further increasing the risk of falls and fractures in osteoporotic individuals.

Osteoporosis is defined as bone mineral density (BMD) of the spine or hip 2.5 standard deviations (SD) below the mean value of a normal young population or as a previous fragility fracture, irrespective of BMD.

FOSAVANCE study

The effect of FOSAVANCE on vitamin D status was demonstrated in a 15-week, multinational study that enrolled 682 osteoporotic post-menopausal women (serum 25-hydroxyvitamin D at baseline: mean, 56 nmol/l [22.3 ng/ml]; range, 22.5-225 nmol/l [9-90 ng/ml]). Patients received FOSAVANCE (alendronate 70 mg/vitamin D₃ 2800 IU) (n=350) or FOSAMAX (alendronate) 70 mg (n=332) once a week; additional vitamin D supplements were prohibited. After 15 weeks of treatment, the mean serum 25-hydroxyvitamin D levels were significantly higher (26 %) in the FOSAVANCE group (56 nmol/l [23 ng/ml]) than in the alendronate-only group (46 nmol/l [18.2 ng/ml]). The percentage of patients with vitamin D insufficiency (serum 25-hydroxyvitamin D < 37.5 nmol/l [< 15 ng/ml]) was significantly reduced by 62.5 % with FOSAVANCE vs. alendronate-only (12 % vs. 32 %, respectively), through week 15. The percentage of patients with vitamin D deficiency (serum 25-hydroxyvitamin D < 22.5 nmol/l [< 9 ng/ml]) was significantly reduced by 92 % with FOSAVANCE vs. alendronate-only (1 % vs 13 %, respectively). In this study, mean 25-hydroxyvitamin D levels in patients with vitamin D insufficiency at baseline (25- hydroxyvitamin D, 22.5 to 37.5 nmol/l [9 to < 15 ng/ml]) increased from 30 nmol/l (12.1 ng/ml) to 40 nmol/l (15.9 ng/ml) at week 15 in the FOSAVANCE group (n=75) and decreased from 30 nmol/l (12.0 ng/ml) at baseline to 26 nmol/l (10.4 ng/ml) at week 15 in the alendronate-only group (n=70). There were no differences in mean serum calcium, phosphate, or 24-hour urine calcium between treatment groups.
Alendronate studies

The therapeutic equivalence of alendronate once weekly 70 mg (n=519) and alendronate 10 mg daily (n=370) was demonstrated in a one-year multicentre study of post-menopausal women with osteoporosis. The mean increases from baseline in lumbar spine BMD at one year were 5.1 % (95 % CI: 4.8, 5.4 %) in the 70 mg once-weekly group and 5.4 % (95 % CI: 5.0, 5.8 %) in the 10 mg daily group. The mean BMD increases were 2.3 % and 2.9 % at the femoral neck and 2.9 % and 3.1 % at the total hip in the 70 mg once weekly and 10 mg daily groups, respectively. The two treatment groups were also similar with regard to BMD increases at other skeletal sites.

The effects of alendronate on bone mass and fracture incidence in post-menopausal women were examined in two initial efficacy studies of identical design (n=994) as well as in the Fracture Intervention Trial (FIT: n=6,459).

In the initial efficacy studies, the mean BMD increases with alendronate 10 mg/day relative to placebo at three years were 8.8 %, 5.9 % and 7.8 % at the spine, femoral neck and trochanter, respectively. Total body BMD also increased significantly. There was a 48 % reduction (alendronate 3.2 % vs placebo 6.2 %) in the proportion of patients treated with alendronate experiencing one or more vertebral fractures relative to those treated with placebo. In the two-year extension of these studies BMD at the spine and trochanter continued to increase and BMD at the femoral neck and total body were maintained.

FIT consisted of two placebo-controlled studies using alendronate daily (5 mg daily for two years and 10 mg daily for either one or two additional years):

- FIT 1: A three-year study of 2,027 patients who had at least one baseline vertebral (compression) fracture. In this study alendronate daily reduced the incidence of ≥1 new vertebral fracture by 47 % (alendronate 7.9 % vs. placebo 15.0 %). In addition, a statistically significant reduction was found in the incidence of hip fractures (1.1 % vs. 2.2 %, a reduction of 51 %).

- FIT 2: A four-year study of 4,432 patients with low bone mass but without a baseline vertebral fracture. In this study, a significant difference was observed in the analysis of the subgroup of osteoporotic women (37 % of the global population who correspond with the above definition of osteoporosis) in the incidence of hip fractures (alendronate 1.0 % vs. placebo 2.2 %, a reduction of 56 %) and in the incidence of ≥1 vertebral fracture (2.9 % vs. 5.8 %, a reduction of 50 %).

5.2. Pharmacokinetic properties

Alendronate

Absorption

Relative to an intravenous reference dose, the oral mean bioavailability of alendronate in women was 0.64 % for doses ranging from 5 to 70 mg when administered after an overnight fast and two hours before a standardised breakfast. Bioavailability was decreased similarly to an estimated 0.46 % and 0.39 % when alendronate was administered one hour or half an hour before a standardised breakfast. In osteoporosis studies, alendronate was effective when administered at least 30 minutes before the first food or beverage of the day.

The alendronate component in the FOSAVANCE combination tablet is bioequivalent to the alendronate 70 mg tablet.

Bioavailability was negligible whether alendronate was administered with, or up to two hours after, a standardised breakfast. Concomitant administration of alendronate with coffee or orange juice reduced bioavailability by approximately 60 %.
In healthy subjects, oral prednisone (20 mg three times daily for five days) did not produce a clinically meaningful change in oral bioavailability of alendronate (a mean increase ranging from 20 % to 44 %).

**Distribution**

Studies in rats show that alendronate transiently distributes to soft tissues following 1 mg/kg intravenous administration but is then rapidly redistributed to bone or excreted in the urine. The mean steady-state volume of distribution, exclusive of bone, is at least 28 litres in humans. Concentrations of alendronate in plasma following therapeutic oral doses are too low for analytical detection (< 5 ng/ml). Protein binding in human plasma is approximately 78 %.

**Biotransformation**

There is no evidence that alendronate is metabolised in animals or humans.

**Elimination**

Following a single intravenous dose of [14C]alendronate, approximately 50 % of the radioactivity was excreted in the urine within 72 hours and little or no radioactivity was recovered in the faeces. Following a single 10 mg intravenous dose, the renal clearance of alendronate was 71 ml/min, and systemic clearance did not exceed 200 ml/min. Plasma concentrations fell by more than 95 % within six hours following intravenous administration. The terminal half-life in humans is estimated to exceed ten years, reflecting release of alendronate from the skeleton. Alendronate is not excreted through the acidic or basic transport systems of the kidney in rats, and thus it is not anticipated to interfere with the excretion of other medicinal products by those systems in humans.

**Colecalciferol**

**Absorption**

In healthy adult subjects (males and females), following administration of FOSAVANCE after an overnight fast and two hours before a meal, the mean area under the serum-concentration-time curve (AUC0-120 hrs) for vitamin D3 (unadjusted for endogenous vitamin D3 levels) was 296.4 ng•hr/ml. The mean maximal serum concentration (Cmax) of vitamin D3 was 5.9 ng/ml, and the median time to maximal serum concentration (Tmax) was 12 hours. The bioavailability of the 2800 IU vitamin D3 in FOSAVANCE is similar to 2800 IU vitamin D3 administered alone.

**Distribution**

Following absorption, vitamin D3 enters the blood as part of chylomicrons. Vitamin D3 is rapidly distributed mostly to the liver where it undergoes metabolism to 25-hydroxyvitamin D3, the major storage form. Lesser amounts are distributed to adipose and muscle tissue and stored as vitamin D3 at these sites for later release into the circulation. Circulating vitamin D3 is bound to vitamin D-binding protein.

**Biotransformation**

Vitamin D3 is rapidly metabolized by hydroxylation in the liver to 25-hydroxyvitamin D3, and subsequently metabolized in the kidney to 1,25-dihydroxyvitamin D3, which represents the biologically active form. Further hydroxylation occurs prior to elimination. A small percentage of vitamin D3 undergoes glucuronidation prior to elimination.

**Elimination**

When radioactive vitamin D3 was administered to healthy subjects, the mean urinary excretion of radioactivity after 48 hours was 2.4 %, and the mean faecal excretion of radioactivity after 4 days was 4.9 %. In both cases, the excreted radioactivity was almost exclusively as metabolites of the parent. The mean half-life of vitamin D3 in the serum following an oral dose of FOSAVANCE is approximately 24 hours.
Characteristics in patients
Preclinical studies show that alendronate that is not deposited in bone is rapidly excreted in the urine.
No evidence of saturation of bone uptake was found after chronic dosing with cumulative intravenous
doses up to 35 mg/kg in animals. Although no clinical information is available, it is likely that, as in
animals, elimination of alendronate via the kidney will be reduced in patients with impaired renal
function. Therefore, somewhat greater accumulation of alendronate in bone might be expected in
patients with impaired renal function (see section 4.2).

5.3 Preclinical safety data
No preclinical studies with the combination of alendronate and colecalciferol have been conducted.

Alendronate
Preclinical data reveal no special hazard for humans based on conventional studies of safety
pharmacology, repeated dose toxicity, genotoxicity and carcinogenic potential. Studies in rats have
shown that treatment with alendronate during pregnancy was associated with dystocia in dams during
parturition which was related to hypocalcaemia. In studies, rats given high doses showed an increased
incidence of incomplete foetal ossification. The relevance to humans is unknown.

Colecalciferol
At doses far higher than the human therapeutic range, reproductive toxicity has been observed in
animal studies.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients
Microcrystalline cellulose (E460)
Lactose anhydrous
Medium chain triglycerides
Gelatin
Croscarmellose sodium
Sucrose
Colloidal silicon dioxide
Magnesium stearate (E572)
Butylated hydroxytoluene (E321)
Modified starch (maize)
Sodium aluminium silicate (E554)

6.2 Incompatibilities
Not applicable.

6.3 Shelf life
18 months.

6.4 Special precautions for storage
Store in the original blister in order to protect from moisture and light.

6.5 Nature and contents of container
Wallet with sealed aluminium/aluminium blisters, in cartons containing 2, 4, 6 (3 wallets x 2 tablets),
12 (3 wallets x 4 tablets) or 40 (10 wallets x 4 tablets) tablets.
Not all pack sizes may be marketed.

6.6 Instructions for use and handling

No special requirements.

7. MARKETING AUTHORIZATION HOLDER

Merck Sharp & Dohme Ltd.
Hertford Road, Hoddesdon
Hertfordshire EN11 9BU
United Kingdom

8. MARKETING AUTHORIZATION NUMBER

9. DATE OF FIRST AUTHORIZATION/RENEWAL OF AUTHORIZATION

10. DATE OF REVISION OF THE TEXT
ANNEX II

A. MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE

B. CONDITIONS OF THE MARKETING AUTHORISATION
A MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE

Name and address of the manufacturer responsible for batch release

FROSST IBERICA, S.A. via Complutense, 140 - 28805 Alcalá de Henares – Madrid, Spain

B CONDITIONS OF THE MARKETING AUTHORISATION

• CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE IMPOSED ON THE MARKETING AUTHORISATION HOLDER

Medicinal product subject to medical prescription.

• OTHER CONDITIONS

The holder of this marketing authorisation must inform the European Commission about the marketing plans for the medicinal product authorised by this decision.
ANNEX III

LABELLING AND PACKAGE LEAFLET
A. LABELLING
PARTICULARS TO APPEAR ON THE OUTER PACKAGING OR, WHERE THERE IS NO OUTER PACKAGING, ON THE IMMEDIATE PACKAGING

OUTER PACKAGING – CARTON FOR 1 TRIFOLD PACK OF 2 TABLETS

1. NAME OF THE MEDICINAL PRODUCT

FOSAVANCE tablets
Alendronic acid as alendronate sodium trihydrate and colecalciferol

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each tablet contains:
70 mg alendronic acid as alendronate sodium trihydrate and 70 micrograms (2800 IU) colecalciferol (vitamin D₃).

3. LIST OF EXCIPIENTS

Also contains: lactose anhydrous and sucrose. See package leaflet for further information.

4. PHARMACEUTICAL FORM AND CONTENTS

2 tablets

5. METHOD AND ROUTE(S) OF ADMINISTRATION

For oral use
To be taken once weekly, on the same day each week. Read the package leaflet before use.

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN

Keep out of the reach and sight of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

Once weekly

8. EXPIRY DATE

EXP

9. SPECIAL STORAGE CONDITIONS

Store in the original blister in order to protect from moisture and light.
### 10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

---

### 11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Merck Sharp & Dohme Ltd.
Hertford Road, Hoddesdon
Hertfordshire EN11 9BU
United Kingdom

### 12. MARKETING AUTHORISATION NUMBER(S)

EU/0/00/000/000

### 13. MANUFACTURER'S BATCH NUMBER

Batch

### 14. GENERAL CLASSIFICATION FOR SUPPLY

Medicinal product subject to medical prescription.

### 15. INSTRUCTIONS ON USE
PARTICULARS TO APPEAR ON THE OUTER PACKAGING OR, WHERE THERE IS NO OUTER PACKAGING, ON THE IMMEDIATE PACKAGING

IMMEDIATE PACKAGING – TRIFOLD PACK OF 2 TABLETS

1. NAME OF THE MEDICINAL PRODUCT

FOSAVANCE tablets
Alendronic acid as alendronate sodium trihydrate and colecalciferol

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each tablet contains:
70 mg alendronic acid as alendronate sodium trihydrate and 70 micrograms (2800 IU) colecalciferol (vitamin D$_3$).

3. LIST OF EXCIPIENTS

Also contains: lactose anhydrous and sucrose. See package leaflet for further information.

4. PHARMACEUTICAL FORM AND CONTENTS

2 tablets

5. METHOD AND ROUTE(S) OF ADMINISTRATION

For oral use.

Important information

How to take FOSAVANCE tablets

1. Take one tablet once a week
2. Choose the day of the week that best fits your schedule. When you get out of bed on the day you have chosen, and before taking your first food, drink or other medicines, swallow (do not chew or suck) one FOSAVANCE tablet with a full glass of water (not mineral water).
3. Continue your morning activities. You can sit, stand or walk – just stay fully upright. Don’t lie down, eat, drink or take other medicines for at least 30 minutes. Do not lie down until after your first food of the day.
4. Remember, take FOSAVANCE once each week on that same day for as long as your doctor prescribes it.

If you miss a dose, take only one FOSAVANCE tablet on the morning after you remember. Do not take two tablets on the same day. Return to taking one tablet once a week, as originally scheduled on your chosen day.

There is important additional information about how to take FOSAVANCE in the enclosed package leaflet. Please read it carefully.

Take one tablet once a week
Mark the day of the week that best fits your schedule:
MON       FRI
TUE       SAT
WED       SUN
THU

WEEK 1. Date: ____
WEEK 2. Date: _____
TIME TO REFILL

For your convenience, place a sticker on your calendar each week as a reminder to take your FOSAVANCE.

FOSAVANCE
WEEK 1
FOSAVANCE
WEEK 2
TIME TO REFILL

To remove, push tablets through from this side.
To remove, push tablets through from other side.

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN

Keep out of the reach and sight of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

Once Weekly

8. EXPIRY DATE

EXP

9. SPECIAL STORAGE CONDITIONS

Store in the original blister in order to protect from moisture and light.

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Merck Sharp & Dohme Ltd.
Hertford Road, Hoddesdon
Hertfordshire EN11 9BU
United Kingdom
<table>
<thead>
<tr>
<th></th>
<th><strong>12. MARKETING AUTHORISATION NUMBER(S)</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>EU/0/00/0000000</td>
</tr>
<tr>
<td></td>
<td><strong>13. MANUFACTURER’S BATCH NUMBER</strong></td>
</tr>
<tr>
<td></td>
<td>Batch</td>
</tr>
<tr>
<td></td>
<td><strong>14. GENERAL CLASSIFICATION FOR SUPPLY</strong></td>
</tr>
<tr>
<td></td>
<td>Medicinal product subject to medical prescription.</td>
</tr>
<tr>
<td></td>
<td><strong>15. INSTRUCTIONS ON USE</strong></td>
</tr>
</tbody>
</table>
PARTICULARS TO APPEAR ON THE OUTER PACKAGING OR, WHERE THERE IS NO OUTER PACKAGING, ON THE IMMEDIATE PACKAGING

OUTER PACKAGING – CARTON FOR 1 TRIFOLD PACK OF 4 TABLETS

1. NAME OF THE MEDICINAL PRODUCT

FOSAVANCE tablets
Alendronic acid as alendronate sodium trihydrate and colecalciferol

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each tablet contains:
70 mg alendronic acid as alendronate sodium trihydrate and 70 micrograms (2800 IU) colecalciferol (vitamin D₃).

3. LIST OF EXCIPIENTS

Also contains: lactose anhydrous and sucrose. See package leaflet for further information.

4. PHARMACEUTICAL FORM AND CONTENTS

4 tablets

5. METHOD AND ROUTE(S) OF ADMINISTRATION

For oral use.
To be taken once weekly, on the same day each week. Read the package leaflet before use.

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN

Keep out of the reach and sight of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

Once weekly

8. EXPIRY DATE

EXP

9. SPECIAL STORAGE CONDITIONS

Store in the original blister in order to protect from moisture and light.
10. **SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE**

---

11. **NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Merck Sharp & Dohme Ltd.
Hertford Road, Hoddesdon
Hertfordshire EN11 9BU
United Kingdom

12. **MARKETING AUTHORISATION NUMBER(S)**

EU/0/00/000/000

13. **MANUFACTURER'S BATCH NUMBER**

Batch

14. **GENERAL CLASSIFICATION FOR SUPPLY**

Medicinal product subject to medical prescription.

15. **INSTRUCTIONS ON USE**
PARTICULARS TO APPEAR ON THE OUTER PACKAGING OR, WHERE THERE IS NO OUTER PACKAGING, ON THE IMMEDIATE PACKAGING

IMMEDIATE PACKAGING – TRIFOLD PACK OF 4 TABLETS

1. NAME OF THE MEDICINAL PRODUCT

FOSAVANCE tablets
Alendronic acid as alendronate sodium trihydrate and colecalciferol

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each tablet contains:
70 mg alendronic acid as alendronate sodium trihydrate and 70 micrograms (2800 IU) colecalciferol (vitamin D₃).

3. LIST OF EXCIPIENTS

Also contains: lactose anhydrous and sucrose. See package leaflet for further information.

4. PHARMACEUTICAL FORM AND CONTENTS

4 tablets

5. METHOD AND ROUTE(S) OF ADMINISTRATION

For oral use.

Important information

How to take FOSAVANCE tablets

1. Take one tablet once a week
2. Choose the day of the week that best fits your schedule. When you get out of bed on the day you have chosen, and before taking your first food, drink or other medicines, swallow (do not chew or suck) one FOSAVANCE tablet with a full glass of water (not mineral water).
3. Continue your morning activities. You can sit, stand or walk – just stay fully upright. Don’t lie down, eat, drink or take other medicines for at least 30 minutes. Do not lie down until after your first food of the day.
4. Remember, take FOSAVANCE once each week on that same day for as long as your doctor prescribes it.

If you miss a dose, take only one FOSAVANCE tablet on the morning after you remember. Do not take two tablets on the same day. Return to taking one tablet once a week, as originally scheduled on your chosen day.

There is important additional information about how to take FOSAVANCE in the enclosed package leaflet. Please read it carefully.

Take one tablet once a week
Mark the day of the week that best fits your schedule:

MON   FRI
TUE   SAT
WED   SUN
THU

WEEK 1. Date: ____
WEEK 2. Date: ____
WEEK 3. Date: ____
WEEK 4. Date: ____
TIME TO REFILL

For your convenience, place a sticker on your calendar each week as a reminder to take your FOSAVANCE.

FOSAVANCE
WEEK 1
FOSAVANCE WEEK 2
FOSAVANCE
WEEK 3
FOSAVANCE TIME TO REFILL
WEEK 4

To remove, push tablets through from this side.
To remove, push tablets through from other side.

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN

Keep out of the reach and sight of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

Once weekly

8. EXPIRY DATE

EXP

9. SPECIAL STORAGE CONDITIONS

Store in the original blister in order to protect from moisture and light.

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Merck Sharp & Dohme Ltd.
Hertford Road, Hoddesdon
12. MARKETING AUTHORISATION NUMBER(S)

EU/0/00/000/000

13. MANUFACTURER’S BATCH NUMBER

Batch

14. GENERAL CLASSIFICATION FOR SUPPLY

Medicinal product subject to medical prescription.

15. INSTRUCTIONS ON USE

--
PARTICULARS TO APPEAR ON THE OUTER PACKAGING OR, WHERE THERE IS NO OUTER PACKAGING, ON THE IMMEDIATE PACKAGING

OUTER PACKAGING – CARTON FOR 3 TRIFOLD PACKS OF 2 TABLETS (3 X 2 tablets)

1. NAME OF THE MEDICINAL PRODUCT

FOSAVANCE tablets
Alendronic acid as alendronate sodium trihydrate and colecalciferol

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each tablet contains:
70 mg alendronic acid as alendronate sodium trihydrate and 70 micrograms (2800 IU) colecalciferol (vitamin D₃).

3. LIST OF EXCIPIENTS

Also contains: lactose anhydrous and sucrose. See package leaflet for further information.

4. PHARMACEUTICAL FORM AND CONTENTS

6 tablets

5. METHOD AND ROUTE(S) OF ADMINISTRATION

For oral use
To be taken once weekly, on the same day each week. Read the package leaflet before use.

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN

Keep out of the reach and sight of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

Once weekly

8. EXPIRY DATE

EXP

9. SPECIAL STORAGE CONDITIONS

Store in the original blister in order to protect from moisture and light.
10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
Merck Sharp & Dohme Ltd.
Hertford Road, Hoddesdon
Hertfordshire EN11 9BU
United Kingdom

12. MARKETING AUTHORISATION NUMBER(S)
EU/0/00/000/000

13. MANUFACTURER'S BATCH NUMBER
Batch

14. GENERAL CLASSIFICATION FOR SUPPLY
Medicinal product subject to medical prescription

15. INSTRUCTIONS ON USE
PARTICULARS TO APPEAR ON THE OUTER PACKAGING OR, WHERE THERE IS NO OUTER PACKAGING, ON THE IMMEDIATE PACKAGING

OUTER PACKAGING – CARTON FOR 3 TRIFOLD PACKS OF 4 TABLETS (3 X 4 tablets)

1. NAME OF THE MEDICINAL PRODUCT

FOSAVANCE tablets
Alendronic acid as alendronate sodium trihydrate and colecalciferol

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each tablet contains:
70 mg alendronic acid as alendronate sodium trihydrate and 70 micrograms (2800 IU) colecalciferol (vitamin D₃).

3. LIST OF EXCIPIENTS

Also contains: lactose anhydrous and sucrose. See package leaflet for further information.

4. PHARMACEUTICAL FORM AND CONTENTS

12 tablets

5. METHOD AND ROUTE(S) OF ADMINISTRATION

For oral use.
To be taken once weekly, on the same day each week. Read the package leaflet before use.

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN

Keep out of the reach and sight of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

Once weekly

8. EXPIRY DATE

EXP

9. SPECIAL STORAGE CONDITIONS

Store in the original blister in order to protect from moisture and light.
<table>
<thead>
<tr>
<th>10.</th>
<th>SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</th>
</tr>
</thead>
<tbody>
<tr>
<td>11.</td>
<td>NAME AND ADDRESS OF THE MARKETING AUTHORIZATION HOLDER</td>
</tr>
<tr>
<td></td>
<td>Merck Sharp &amp; Dohme Ltd.</td>
</tr>
<tr>
<td></td>
<td>Hertford Road, Hoddesdon</td>
</tr>
<tr>
<td></td>
<td>Hertfordshire EN11 9BU</td>
</tr>
<tr>
<td></td>
<td>United Kingdom</td>
</tr>
<tr>
<td>12.</td>
<td>MARKETING AUTHORIZATION NUMBER(S)</td>
</tr>
<tr>
<td></td>
<td>EU/0/00/000/000</td>
</tr>
<tr>
<td>13.</td>
<td>MANUFACTURER'S BATCH NUMBER</td>
</tr>
<tr>
<td></td>
<td>Batch</td>
</tr>
<tr>
<td>14.</td>
<td>GENERAL CLASSIFICATION FOR SUPPLY</td>
</tr>
<tr>
<td></td>
<td>Medicinal product subject to medical prescription.</td>
</tr>
<tr>
<td>15.</td>
<td>INSTRUCTIONS ON USE</td>
</tr>
</tbody>
</table>
**PARTICULARS TO APPEAR ON THE OUTER PACKAGING OR, WHERE THERE IS NO OUTER PACKAGING, ON THE IMMEDIATE PACKAGING**

OUTER PACKAGING – CARTON FOR 10 TRIFOLD PACKS OF 4 TABLETS (10 x 4 tablets)

<table>
<thead>
<tr>
<th>1. NAME OF THE MEDICINAL PRODUCT</th>
</tr>
</thead>
<tbody>
<tr>
<td>FOSAVANCE tablets</td>
</tr>
<tr>
<td>Alendronic acid as alendronate sodium trihydrate and colecalciferol</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>2. STATEMENT OF ACTIVE SUBSTANCE(S)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Each tablet contains:</td>
</tr>
<tr>
<td>70 mg alendronic acid as alendronate sodium trihydrate and 70 micrograms (2800 IU) colecalciferol (vitamin D₃).</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>3. LIST OF EXCIPIENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Also contains: lactose anhydrous and sucrose. See package leaflet for further information.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>4. PHARMACEUTICAL FORM AND CONTENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>40 tablets</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>5. METHOD AND ROUTE(S) OF ADMINISTRATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>For oral use.</td>
</tr>
<tr>
<td>To be taken once weekly, on the same day each week. Read the package leaflet before use</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN</th>
</tr>
</thead>
<tbody>
<tr>
<td>Keep out of the reach and sight of children.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>7. OTHER SPECIAL WARNING(S), IF NECESSARY</th>
</tr>
</thead>
<tbody>
<tr>
<td>Once weekly</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>8. EXPIRY DATE</th>
</tr>
</thead>
<tbody>
<tr>
<td>EXP</td>
</tr>
</tbody>
</table>
9. SPECIAL STORAGE CONDITIONS

Store in the original blister in order to protect from moisture and light.

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

--

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Merck Sharp & Dohme Ltd.
Hertford Road, Hoddesdon
Hertfordshire EN11 9BU
United Kingdom

12. MARKETING AUTHORISATION NUMBER(S)

EU/0/00/000/000

13. MANUFACTURER’S BATCH NUMBER

Batch

14. GENERAL CLASSIFICATION FOR SUPPLY

Medicinal product subject to medical prescription.

15. INSTRUCTIONS ON USE
PACKAGE LEAFLET

Read all of this leaflet carefully before you start taking this medicine, even if this is a repeat prescription.
- Keep this leaflet. You may need to read it again.
- If you have further questions, please ask your doctor or your pharmacist.
- This medicine has been prescribed for you personally and you should not pass it on to others. It may harm them, even if their symptoms are the same as yours.
- It is particularly important to understand the information in section 3. HOW TO TAKE FOSAVANCE, before taking this medicine.

In this leaflet:
1. What is FOSAVANCE and what is it used for?
2. Before you take FOSAVANCE
3. How to take FOSAVANCE
4. Possible side effects
5. Storing FOSAVANCE
6. Further information

FOSAVANCE tablets
alendronic acid as alendronate sodium trihydrate and colecalciferol

Active substances
The active substances are alendronate sodium trihydrate and colecalciferol (vitamin D₃). Each tablet contains 70 mg alendronic acid as alendronate sodium trihydrate and 70 micrograms (2800 IU) colecalciferol (vitamin D₃).

Other ingredients
Microcrystalline cellulose (E460), lactose anhydrous, medium chain triglycerides, gelatin, croscarmellose sodium, sucrose, colloidal silicon dioxide, magnesium stearate (E572) butylated hydroxytoluene (E321), modified starch (maize), and sodium aluminium silicate (E554).

Marketing Authorisation Holder
Merck Sharp & Dohme Limited
Hertford Road, Hoddesdon
Hertfordshire EN11 9BU
United Kingdom

Manufacturer
FROSST IBERICA, S.A.
Via Complutense, 140
E-28805 Alcalá de Henares
Madrid
Spain

1. WHAT IS FOSAVANCE AND WHAT IS IT USED FOR?

What is FOSAVANCE?
FOSAVANCE is a tablet containing the two active substances, alendronate sodium trihydrate and vitamin D₃.

What is alendronate?
Alendronate belongs to a group of non-hormonal medicines called bisphosphonates. Alendronate prevents the loss of bone that occurs in women after they have been through the menopause, and helps to rebuild bone. It reduces the risk of spine and hip fractures.
What is vitamin D?
Vitamin D is an essential nutrient, required for calcium absorption and healthy bones. The body can only absorb calcium properly from our food if it has enough vitamin D. Very few foods contain vitamin D. The main source is through exposure to summer sunlight, which makes vitamin D in our skin. As we get older our skin makes less vitamin D. Too little vitamin D may lead to bone loss and osteoporosis. Severe vitamin D deficiency may cause muscle weakness which can lead to falls and a greater risk of fractures.

What FOSAVANCE looks like and how it is supplied
FOSAVANCE tablets are available as capsule-shaped, white to off-white tablets marked with an outline of a bone image on one side and ‘710’ on the other.

The tablets are supplied in wallets with sealed aluminium blisters in cartons in the following pack sizes
- 2 tablets (1 wallet containing 2 tablets in aluminium blisters)
- 4 tablets (1 wallet containing 4 tablets in aluminium blisters)
- 6 tablets (3 wallets each containing 2 tablets in aluminium blisters).
- 12 tablets (3 wallets each containing 4 tablets in aluminium blisters).
- 40 tablets (10 wallets each containing 4 tablets in aluminium blisters).

Not all pack sizes may be marketed.

What is FOSAVANCE used for?
Your doctor has prescribed FOSAVANCE to treat your osteoporosis and because you are at risk of vitamin D insufficiency. FOSAVANCE reduces the risk of spine and hip fractures.

FOSAVANCE is a once weekly treatment.

What is osteoporosis?
Osteoporosis is a thinning and weakening of the bones. It is common in women after the menopause. At the menopause, the ovaries stop producing the female hormone, oestrogen, which helps to keep a woman’s skeleton healthy. As a result, bone loss occurs and bones become weaker. The earlier a woman reaches the menopause, the greater the risk of osteoporosis.

Early on, osteoporosis usually has no symptoms. If left untreated, however, it can result in broken bones. Although these usually hurt, breaks in the bones of the spine may go unnoticed until they cause height loss. Broken bones can happen during normal, everyday activity, such as lifting, or from minor injury that would not generally break normal bone. Broken bones usually occur at the hip, spine, or wrist and can lead not only to pain but also to considerable problems like stooped posture (‘dowager’s hump’) and loss of mobility.

How can osteoporosis be treated?
Osteoporosis can be treated and it is never too late to begin treatment. FOSAVANCE not only prevents the loss of bone but actually helps to rebuild bone you may have lost and reduces the risk of bones breaking in the spine and hip.

As well as your treatment with FOSAVANCE, your doctor may suggest you make changes to your lifestyle to help your condition, such as:

Stopping smoking
Smoking appears to increase the rate at which you lose bone and, therefore, may increase your risk of broken bones.

Exercise
Like muscles, bones need exercise to stay strong and healthy. Consult your doctor before you begin any exercise programme.

Eating a balanced diet
Your doctor can advise you about your diet or whether you should take any dietary supplements.
2. **BEFORE YOU TAKE FOSAVANCE**

**Do not take FOSAVANCE:**
(1) if you are hypersensitive (allergic) to alendronate sodium trihydrate, colecalciferol or any of the other ingredients
(2) if you have certain problems with your gullet (oesophagus - the tube that connects your mouth with your stomach) such as narrowing or difficulty swallowing
(3) if you cannot stand or sit upright for at least 30 minutes
(4) if your doctor has told you that you have low blood calcium

If you think any of these apply to you, do not take the tablets. Talk to your doctor first and follow the advice given.

**Take special care with FOSAVANCE:**
It is important to tell your doctor before taking FOSAVANCE
- if you suffer from kidney problems
- if you have any allergies
- if you have any swallowing or digestive problems
- if you have low blood calcium levels

Irritation, inflammation or ulceration of the gullet (oesophagus – the tube that connects your mouth with your stomach) often with symptoms of chest pain, heartburn, or difficulty or pain upon swallowing may occur, especially if patients do not drink a full glass of water and/or if they lie down less than 30 minutes after taking FOSAVANCE. These side effects may worsen if patients continue to take FOSAVANCE after developing these symptoms.

**Taking FOSAVANCE with food and drink:**
It is likely that food and beverages (including mineral water) will make FOSAVANCE less effective if taken at the same time. Therefore, it is important that you follow the advice given in section 3. HOW TO TAKE FOSAVANCE.

**Children and adolescents**
FOSAVANCE should not be given to children and adolescents.

**Pregnancy**
You should not take FOSAVANCE if you are or think you may be pregnant.
FOSAVANCE is only intended for use in postmenopausal women.

**Breast-feeding**
You should not take FOSAVANCE if you are breast-feeding. FOSAVANCE is only intended for use in postmenopausal women.

**Driving and using machines:**
FOSAVANCE should not affect your ability to drive or operate machines.

**Important information about some of the ingredients of FOSAVANCE**
FOSAVANCE contains lactose and sucrose. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.

**Taking other medicines:**
It is likely that calcium supplements, antacids, and some oral medicines will interfere with the absorption of FOSAVANCE if taken at the same time. Therefore, it is important that you follow the advice given in section 3. HOW TO TAKE FOSAVANCE.
It is likely that certain medicines or food additives may prevent the vitamin D in FOSAVANCE from getting into your body, including artificial fat substitutes, mineral oils, orlistat and the cholesterol-lowering medicines, cholestyramine and colestipol. Medicines for fits (seizures) may decrease the effectiveness of vitamin D. Additional vitamin D supplements may be considered on an individual basis.

Always tell your doctor about all medicines you are taking or plan to take, including any obtained without a prescription.

3. HOW TO TAKE FOSAVANCE

Take one FOSAVANCE tablet once a week.

Follow these instructions carefully to make sure you will benefit from FOSAVANCE.

1) Choose the day of the week that best fits your schedule. Every week, take one FOSAVANCE tablet on your chosen day.

It is very important to follow instructions 2), 3), 4) and 5) to help the FOSAVANCE tablet reach your stomach quickly and help reduce the chance of irritating your gullet (oesophagus - the tube that connects your mouth with your stomach).

2) After getting up for the day and before taking any food, drink, or other medicine, swallow your FOSAVANCE tablet with a full glass of water only (not mineral water) (not less than 200 ml or 7 fl. oz.).
   • Do not take with mineral water (still or sparkling).
   • Do not take with coffee or tea.
   • Do not take with juice or milk.

Do not chew the tablet or allow it to dissolve in your mouth.

3) Do not lie down — stay fully upright (sitting, standing or walking) — for at least 30 minutes after swallowing the tablet. Do not lie down until after your first food of the day.

4) Do not take FOSAVANCE at bedtime or before getting up for the day.

5) If you develop difficulty or pain upon swallowing, chest pain, or new or worsening heartburn, stop taking FOSAVANCE and contact your doctor.

6) After swallowing your FOSAVANCE tablet, wait at least 30 minutes before taking your first food, drink, or other medicine of the day, including antacids, calcium supplements and vitamins. FOSAVANCE is effective only if taken when your stomach is empty.

7) It is important that you continue taking FOSAVANCE for as long as your doctor prescribes the medicine. FOSAVANCE can treat your osteoporosis only if you continue to take the tablets.

If you take more FOSAVANCE than you should:
If you take too many tablets by mistake, drink a full glass of milk and contact your doctor immediately. Do not make yourself vomit, and do not lie down.

If you forget to take FOSAVANCE:
If you miss a dose, just take one tablet on the morning after you remember. Do not take two tablets on the same day. Return to taking one tablet once a week, as originally scheduled on your chosen day.

4. POSSIBLE SIDE EFFECTS
Like all medicines, FOSAVANCE can have side effects.
The following terms are used to describe how often side effects have been reported.
Common (occurring in at least 1 of 100 and less than 1 of 10 patients treated)
Uncommon (occurring in at least 1 of 1000 and less than 1 of 100 patients treated)
Rare (occurring in at least 1 of 10,000 and less than 1 of 1000 patients treated)
Very rare (occurring in less than 1 of 10,000 patients treated)

**Immune system disorders:**
- Rare: allergic reactions such as hives; swelling of the face, lips, tongue and/or throat, possibly causing difficulty breathing or swallowing

**Metabolism and nutrition disorders:**
- Rare: symptoms of low blood calcium levels including muscle cramps or spasms and/or tingling sensation in the fingers or around the mouth

**Nervous system:**
- Common: headache

**Eye disorders:**
- Rare: blurred vision, pain or redness in the eye

**Digestive tract:**
- Common: abdominal pain; uncomfortable feeling in the stomach or belching after eating; constipation; full or bloated feeling in the stomach; diarrhoea; flatulence; heartburn; difficulty swallowing; pain upon swallowing; ulceration of the gullet (oesophagus - the tube that connects your mouth with your stomach) which can cause chest pain, heartburn or difficulty or pain upon swallowing
- Uncommon: nausea; vomiting; irritation or inflammation of the gullet (oesophagus – the tube that connects your mouth with your stomach) or stomach; black or tar-like stools
- Rare: narrowing of the gullet (oesophagus – the tube that connects your mouth with your stomach); mouth ulcers when the tablets have been chewed or sucked; stomach or peptic ulcers (sometimes severe or with bleeding) but it is not sure whether these were caused by FOSAVANCE.

Jaw problems associated with delayed healing and infection, often following tooth extraction.

**Skin:**
- Uncommon: rash; itching; redness of the skin
- Rare: rash made worse by sunlight
- Very rare: severe skin reactions

**Musculoskeletal:**
- Common: bone, muscle and/or joint pain
- Rare: severe bone, muscle and/or joint pain

**General disorders:**
- Rare: transient flu-like symptoms, such as aching muscles, generally feeling unwell and sometimes with fever usually at the start of treatment

Tell your doctor or pharmacist promptly about these or any other unusual symptoms.

It will help if you make a note of what you experienced, when it started and how long it lasted.

If you notice any side effects not mentioned in this leaflet, please inform your doctor or pharmacist.

5. **STORING FOSAVANCE**

Keep out of the reach and sight of children.
Store in the original blister in order to protect from moisture and light.

Do not take the tablets after the expiry date stated on the blister and the carton.

6. FURTHER INFORMATION

For any information about this medicinal product, please contact the local representative of the Marketing Authorisation Holder.

Belgique/België/Belgien: Merck Sharp & Dohme B.V., Succursale belge/Belgisch bijhuis, Chaussée de Waterloo/Waterloosesteenweg 1135, B-1180 Bruxelles/Brussel/Brüssel, Tél/Tel: +32 (0) 2 373 42 11

Česká republika: Merck Sharp & Dohme, IDEA, Inc., Křenova 5, PSČ-162 00 Praha 6, Tel.: +420 233 010 111

Danmark: Merck Sharp & Dohme, Smedeland 8, DK-2600 Glostrup, Tlf: +45 43 28 77 66

Deutschland: MSD SHARP & DOHME GmbH, Lindenplatz 1, D-85540 Haar, Tel: +49 (0) 89 4561 2612

Eesti: Merck Sharp & Dohme OÜ, Peterburi tee 4646, EE-11415 Tallinn, Tel.: +372 613 9750

Ελλάδα: BIANEZ A.E., Οδός Τατσίου, Τρ.Θηρ. 52894, GR-146 10 Νέα Ερυθραία, Τηλ.: +30 210 800911

España: Merck Sharp & Dohme de España, S.A., C/Josefa Valcárcel, 38, E-28027 Madrid, Tel: +34 91 321 06 00

France: Laboratoires Merck Sharp & Dohme – Chibret, 3, Avenue Hoche, F-75114 Paris Cedex 08, Tel: +33 (0) 1 47 54 87 00

Ierland: Merck Sharp and Dohme Limited, Hertford Road, Hoddesdon, Hertfordshire EN11 9BU, UK, Tel: +44 (0) 1992 467272

Ísland: Merck Sharp & Dohme Island ehf., Skógarhlíð 12, IS-105 Reykjavík, Tel: +354 520 8600

Italia: Merck Sharp & Dohme (Italia) S.p.A., via G. Fabbroni, 6, I-00191 Roma, Tel: +39 06 361911

Κύπρος: Μ. Σ. Ιωκοβανος & Σια Λτδ., Οδός Αγίου Νικολάου Αρ. 8, CY-1055 Λευκωσία, Τηλ.: +357 22757188

Latvija: SIA “Merck Sharp & Dohme Latvija”, Skanestes iela 13, LV-Rīga 1013, Tel: +371 7364 224

Lietuva: UAB “Merck Sharp & Dohme”, Geležinių Vilko 18A, LT-01112 Vilnius, Tel.: +370 5 278 02 47

Luxembourg/Luxemburg: Merck Sharp & Dohme B.V., Succursale belge/Belgisch bijhuis, Chaussée de Waterloo/Waterloosesteenweg 1135, B-1180 Bruxelles/Brussel/Brüssel, Tél/Tel: +32 (0) 2 373 42 11

Magyarország: MSD Magyarország Kft., Alkotás u. 50, H-1123 Budapest, Tel.: +36 1 888 53 00

Malta: A.M.Mangion Ltd, New Street off Valletta Road, MT-Luqa LQA 06, Tel: +356 21 442010

Nederland: Merck Sharp & Dohme B.V., Postbus 581, NL-2003 PC Haarlem, Tel: +31 (0) 23 5153153

Norge: MSD (Norge) AS, Solbakken 1, P.O. Box 458 Brakerøya, N-3002 Drammen, Tlf: +47 32 20 73 00

Österreich: Merck Sharp & Dohme GmbH, Donau-City Strasse 6, A-1220 Wien, Tel: +43 (0) 1 26 044

Polska: MSD Polska Sp. z o.o., ul.Chłodna 51, PL- 00-867 Warszawa, Tel.: +48 22 549 51 00

Portugal: Merck Sharp & Dohme, Lda, Quinta da Fonte, Edifício Vasco da Gama (19), P.O. Box 214, Porto Salvo, P-2770-192 Paço de Arcos, Tel: +351 21 4465700

Slovenija: Merck Sharp & Dohme, inovativna zdravila d.o.o., Šmartinske cesta 140, SI-1000 Ljubljana, Tel.: +386 1 5204201

Slovenská republika: Merck Sharp & Dohme IDEA, Inc., Mlynské nivy 43, SK-821 09 Bratislava 2, Tel.: +421 2 58282010

Suomi/Finland: Suomen MSD Oy, Keilaranta 3/Kägelstranden 3, FIN-02150 Espoo/Esbo, Puh/Tel: +358 (0) 9 804650

Sverige: Merck Sharp & Dohme (Sweden) AB, Box 7125, S-192 07 Sollentuna, Tel: +46 (0) 8 626 1400
United Kingdom: Merck Sharp and Dohme Limited, Hertford Road, Hoddesdon, Hertfordshire EN11 9BU, UK, Tel: +44 (0) 1992 467272

This leaflet was last approved on